CAPTRUST Financial Advisors’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

CAPTRUST Financial Advisors’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-100	Closed	–	–	4982
2021 Q3	$0	Hold	100	–	–	﹤0.01%	4819
2021 Q2	$1K	Hold	100	–	–	﹤0.01%	4420
2021 Q1	$0	Hold	100	–	–	﹤0.01%	4514
2020 Q4	$0	Hold	100	–	–	﹤0.01%	3553
2020 Q3	$0	Hold	100	–	–	﹤0.01%	3297
2020 Q2	$0	Buy	+100	New	+$473	﹤0.01%	2918
2019 Q4	–	Sell	-100	Closed	-$1K	–	1911
2019 Q3	$1K	Hold	100	–	–	﹤0.01%	1892
2019 Q2	$1K	Hold	100	–	–	﹤0.01%	1888
2019 Q1	$1K	Hold	100	–	–	﹤0.01%	1776
2018 Q4	$0	Hold	100	–	–	﹤0.01%	1699
2018 Q3	$1K	Hold	100	–	–	﹤0.01%	1533
2018 Q2	$1K	Hold	100	–	–	﹤0.01%	1481
2018 Q1	$1K	Buy	+100	New	+$1.08K	﹤0.01%	1304

Other funds holding ZYNE

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

CAPTRUST Financial Advisors's ZYNE Position: Q4 2021 in Review

CAPTRUST Financial Advisors sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2021, closing a stake of 100 shares.

CAPTRUST Financial Advisors first reported a position in ZYNE in Q1 2018 and held it in 13 quarters. The position peaked at $1K in Q2 2021. 62 funds tracked by Wall St. Rank hold ZYNE as of Q4 2021.

CAPTRUST Financial Advisors reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2021 after selling out during the quarter.
CAPTRUST Financial Advisors sold 100 Zynerba Pharmaceuticals, Inc shares in Q4 2021.
CAPTRUST Financial Advisors first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2018 and held it in 13 quarters.
CAPTRUST Financial Advisors's Zynerba Pharmaceuticals, Inc position peaked at $1K in Q2 2021.
62 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2021.

Based on CAPTRUST Financial Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.